Clinical Trial Update: Deucravacitinib Rosacea [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating deucravacitinib for papulopustular rosacea has been withdrawn. The sponsor listed is Icahn School of Medicine at Mount Sinai.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papulopustular Rosacea

Drugs mentioned

• Sotyktu (Deucravacitinib)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Papulopustular Rosacea | Phase 2 | Status: WITHDRAWN